drugset

drugset / Trial / NCT04512287

PRP for Treatment of Peyronie's Disease

NCT04512287 ↗

Phase 2 Completed 65 enrolled University of Miami

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD).

Timeline

Start: 2021-03-29
Primary completion: 2025-08-11
Completion: 2025-08-11

Publications

Chu KY, Molina ML, Ledesma B, Zucker I, Saltzman RG, Masterson TA, Ramasamy R. A Phase 2 Randomized, Placebo-controlled Crossover Trial to Evaluate Safety and Efficacy of Platelet-rich Plasma Injections for Peyronie's Disease: Clinical Trial Update. Eur Urol Focus. 2023 Jan;9(1):11-13. doi: 10.1016/j.euf.2022.08.017. Epub 2022 Sep 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Platelet Rich Plasma	Other / unclassified	0.5 ml	Other

Indications